Fitomenadion (K1 vitamini) etkileşimleri

K vitamini sınıfından Fitomenadion (K1 vitamini) (Mephyton, AquaMephyton) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 34 belgelenmiş etkileşim var: 5 majör, 26 orta, 3 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (5)

  • Patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage). (Butalbital, aspirin ve kafein etiketi, Kontrendikasyonlar)

  • FenitoinantikonvülsanMajör

    A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (Fenitoin etiketi, Uyarılar ve önlemler)

  • FosfenitoinantikonvülsanMajör

    A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (Fosfenitoin etiketi, Uyarılar ve önlemler)

  • KapesitabinantimetabolitMajör

    WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY and INCREASED RISK OF BLEEDING WITH CONCOMITANT USE OF VITAMIN K ANTAGONISTS Increased risk of serious adverse reactions or death in patients with complete DPD deficiency • Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary. (Kapesitabin etiketi, Kutulu uyarı)

  • RifampisinantibiyotikMajör

    Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (Rifampisin etiketi, Uyarılar)

Orta düzey etkileşimler (26)

  • ApiksabanantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • ArgatrobanantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • BikalutamidandrojenOrta

    Some patients had serious bleeding including intracranial, retroperitoneal, and gastrointestinal requiring blood transfusion and/or administration of vitamin K. (Bikalutamid etiketi, Uyarılar ve önlemler)

  • BivalirudinantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. (Butalbital, aspirin, kafein ve kodein etiketi, Uyarılar ve önlemler)

  • DabigatranantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • EdoksabanantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • EnoksaparinantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • FondaparinuksantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • HeparinantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • KininantimalaryalOrta

    Warfarin and oral anticoagulants Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. (Kinin etiketi, İlaç etkileşimleri)

  • Kolesevelamsafra asidi bağlayıcıOrta

    Vitamin K or Fat-Soluble Vitamin Deficiencies: Colesevelam hydrochloride may decrease absorption of fat-soluble vitamins. (Kolesevelam etiketi, Uyarılar ve önlemler)

  • Levotiroksin ve liyotironintiroid hormonuOrta

    Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Levotiroksin ve liyotironin etiketi, İlaç etkileşimleri)

  • Metimazolantitiroid ilaçOrta

    Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers… (Metimazol etiketi, İlaç etkileşimleri)

  • NeomisinaminoglikozidOrta

    Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Neomisin etiketi, İlaç etkileşimleri)

  • The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (Orlistat etiketi, İlaç etkileşimleri)

  • PentoksifilinmetilksantinOrta

    Increased prothrombin time has been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. (Pentoksifilin etiketi, İlaç etkileşimleri)

  • Propiltiourasilantitiroid ilaçOrta

    Drug Interactions Anticoagulants (oral) : Due to the potential inhibition of vitamin K activity by propylthiouracil, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. (Propiltiourasil etiketi, İlaç etkileşimleri)

  • RivaroksabanantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

  • SefazolinsefalosporinOrta

    Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (Sefazolin etiketi, Uyarılar ve önlemler)

  • SefepimsefalosporinOrta

    Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated. (Sefepim etiketi, Uyarılar ve önlemler)

  • SefiksimsefalosporinOrta

    Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. (Sefiksim etiketi, Uyarılar ve önlemler)

  • SefotetansefalosporinOrta

    Prothrombin time should be monitored and exogenous vitamin K administered as indicated. (Sefotetan etiketi, Uyarılar)

  • SeftriaksonsefalosporinOrta

    Patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during Ceftriaxone for Injection and Dextrose Injection treatment. (Seftriakson etiketi, Uyarılar ve önlemler)

  • In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. (Sugammadeks etiketi, Uyarılar ve önlemler)

  • VarfarinantikoagülanOrta

    Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fitomenadion (K1 vitamini) etiketi, İlaç etkileşimleri)

Minör değinmeler (3)

  • K vitaminiVitamin ve mineralMinör

    Cutaneous Reactions Parenteral administration of vitamin K replacements (including phytonadione injectable emulsion) may cause cutaneous reactions. (Fitomenadion (K1 vitamini) etiketi, Uyarılar ve önlemler)

  • Metilergometrinergot alkaloidiMinör

    Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (Metilergometrin etiketi, Uyarılar)

  • PrimidonantikonvülsanMinör

    Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. (Primidon etiketi, Uyarılar)

Kullandığınız her şeyi Fitomenadion (K1 vitamini) ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.